P28482

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession MK01_HUMAN; P28482;
Entrez ID 5594
GenBank Protein ID NM_002745.4; NM_138957.3;
GenBank Nucleotide ID NP_002736.3; NP_620407.1;
Protein Name Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2)
Gene Name MAPK1; ERK2; PRKM1; PRKM2
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionSerine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The MAPK/ERK cascade p(view all)
Sequence
(Fasta)
MAAAAAAGAG PEMVRGQVFD VGPRYTNLSY IGEGAYGMVC SAYDNVNKVR VAIKKISPFE 60
HQTYCQRTLR EIKILLRFRH ENIIGINDII RAPTIEQMKD VYIVQDLMET DLYKLLKTQH 120
LSNDHICYFL YQILRGLKYI HSANVLHRDL KPSNLLLNTT CDLKICDFGL ARVADPDHDH 180
TGFLTEYVAT RWYRAPEIML NSKGYTKSID IWSVGCILAE MLSNRPIFPG KHYLDQLNHI 240
LGILGSPSQE DLNCIINLKA RNYLLSLPHK NKVPWNRLFP NADSKALDLL DKMLTFNPHK 300
RIEVEQALAH PYLEQYYDPS DEPIAEAPFK FDMELDDLPK EKLKELIFEE TARFQPGYRS 360
361

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1PhosphorylationColon cancer/carcinomaA23786838
[Reference]: Expression levels of COX-2 and VEGF protein and phosphorylation of AKT, ERK1/2, and NF-B P65 were also inhibited
2PhosphorylationSquamous cell carcinoma of the larynxD16865246
[Reference]: Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx.
3PhosphorylationPulmonary carcinoidD15956248
[Reference]: Treatment of carcinoid tumor cells with ZM336372 resulted in progressive phosphorylation of Raf-1, mitogen-activated protein kinase 1/2, and extracellular signal-regulated kinase 1/3.
4PhosphorylationMyelodysplasiaD12529294
[Reference]: We demonstrated higher protein levels of the PI3K subunit p110 in neutrophils from MDS patients and found that though the fMLP-induced phosphorylation of PKB/Akt and ERK1/2 could also be enhanced by pretreatment with GM-CSF in these patients, the degree and kinetics of PKB/Akt and ERK1/2 phosphorylation were significantly disturbed.
5PhosphorylationColon cancer/carcinomatumor tissueP23183114
[Reference]: High nuclear expression of phosphorylated extracellular signal-regulated kinase in tumor cells in colorectal glands is associated with poor outcome in colorectal cancer
6PhosphorylationLiver cancerSK-hep-1 cell lineP23693078
[Reference]: In addition, we observed an effect of ectopic IRTKS expression and PD98059 on HCC proliferation: the result showed that inhibiting ERK phosphorylation could rescue the proliferation-promoting role of IRTKS in the SK-hep-1 and YY-8103 cell lines
7PhosphorylationLymphomacell lineP23620775
[Reference]: In vitro, sorafenib significantly decreased cell proliferation and phosphorylation levels of MAPK and PI3K/Akt pathways while increased apoptotic cell death
8PhosphorylationNon-small cell lung cancer/carcinomaP24096476
[Reference]: Patients with tumors positive for PXN, phosphorylated PXN, phosphorylated ERK and Bcl-2 more commonly showed a poorer response to cisplatin-based chemotherapy than did patients with negative tumors
9PhosphorylationBrain cancer/tumorP12388552
[Reference]: The CXCR4 on glioma lines is a signaling receptor in that its agonist, stromal cell-derived factor-1 (SDF-1; CXCL12), produced rapid phosphorylation of mitogen-activated protein kinases. Furthermore, SDF-2 induced the phosphorylation of Akt (protein kinase B), a kinase associated with survival, and prevented the apoptosis of glioma cells when serum was withdrawn from the culture medium.
10PhosphorylationAstrocytoma/Astrocytoma glioblastomaP17327470
[Reference]: Treatment with PD98059 and U0126 (MEK inhibitors) inhibited not only ET-1-induced cell proliferation but also ET-1-activated phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK1/2) in U373MG astrocytoma cells.
11PhosphorylationBladder cancerP24375195
[Reference]: We also examined the level of ERK phosphorylation. We found that CRKL transfection led to the increase of ERK phosphorylation level, without significant change of total ERK.
12PhosphorylationRhabdomyosarcomaP14633723
[Reference]: We found that although HGF, similar to SDF-1, did not affect the proliferation of RMS cells, it induced in several of them: (a) locomotion; (b) stress fiber formation; (c) chemotaxis; (d) adhesion to human umbilical vein endothelial cells; (e) trans-Matrigel invasion and matrix metalloproteinase secretion; and (f) phosphorylation of mitogen-activated protein kinase p42/44 and AKT.
13PhosphorylationThyroid cancer/carcinomaP11299771
[Reference]: We have previously reported that apigenin inhibits the growth of thyroid cancer cells by attenuating epidermal growth factor receptor (EGF-R) tyrosine phosphorylation and phosphorylation of ERK mitogen-activated protein (MAP) kinase.
14PhosphorylationAcute myeloid leukaemia/Acute myelogenous leukemiaP23840454
[Reference]: we have shown that green tea polyphenols including (-)-epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin (EGC), and (-)-epicatechin-3-gallate (ECG) suppress the proliferation of AML cells. Interestingly, EGCG, EGC and ECG showed the inhibition of FLT3 expression in cell lines harboring FLT3 mutations
15PhosphorylationGlioblastomatumor tissueU23115159
[Reference]: High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era
16PhosphorylationOvarian cancer/carcinomatumor tissueU23285101
[Reference]: In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001),
17PhosphorylationPancreatic cancer/carcinoma/adenocarcinomaU21678462
[Reference]: Inhibiting ERK1/2 signaling in pancreatic cancer cells decreases pancreatic cancer cell invasion
18PhosphorylationBreast cancer/tumor/carcinomaU10216485; 24375195
[Reference]: Mek1 and especially Mek2 protein expression, as well as MAP kinase kinase activity as determined by phosphorylation of kinase-inactive Erk [GST-K71A] were increased in cancer samples.
19PhosphorylationCrohn's diseaseU23970928
[Reference]: The result shows that the phosphorylation of the Ras, Raf-1, MEK-1, and ERK-1/2 proteins and the expression of the corresponding mRNAs in the colon tissue of CD rat were significantly higher than the normal control group.
20PhosphorylationNeuroblastomaU15972965
[Reference]: The suppression of activated ALK in neuroblastoma cells by RNA interference significantly reduced the phosphorylation of ShcC, mitogen-activated protein kinases, and Akt, inducing rapid apoptosis in the cells.
21PhosphorylationAdenomaU21989899
[Reference]: There was also a statistically significant increase in nuclear staining intensity for pERK (p<0.001) and pMEK (p<0.001) in adenomas compared to non-neoplastic mucosa
22PhosphorylationLung cancer/carcinomaU24286320
[Reference]: We also observed increased extracellular signal-regulated kinase (ERK) phosphorylation and enhanced proliferation of TRAP1 overexpressing cells
23PhosphorylationProstate cancer/carcinoma/adenocarcinomaU9927031
[Reference]: We examined 82 primary and metastatic prostate tumor specimens for the presence of activated MAP kinase as a measure of Ras signaling using an antibody that specifically recognizes the dually phosphorylated MAP kinases, ERK1 and ERK2. High levels of activated MAP kinase were observed in high-grade and advanced-stage tumors, suggesting elevated Ras signaling in advanced prostate tumors
24PhosphorylationBipolar disorderU24075327
[Reference]: Western blot and flow cytometry analyses showed increased phosphorylation levels of p65 NF-B subunit, and MAPKs ERK1/2, and p38 in BD patients in euthymia in comparison with controls
25Serine PhosphorylationChoriocarcinomaUS4111466319
[Reference]: We found that cAMP stabilized ICER protein by inhibiting the mitogen-activated protein kinase (MAPK) cascade.
26Threonine PhosphorylationLung cancer/carcinomaPT18523149922
[Reference]: Furthermore, MIG-7 protein inhibited protein phosphatase 2A to sustain Akt/GSK3? phosphorylation and cancer-cell migration/invasion
27Tyrosine PhosphorylationLung cancer/carcinomaPY18723149922
[Reference]: Furthermore, MIG-7 protein inhibited protein phosphatase 2A to sustain Akt/GSK3? phosphorylation and cancer-cell migration/invasion
28Tyrosine PhosphorylationBreast cancer/tumor/carcinomacell lineUY18728415597
[Reference]: Improved cancer-specifc survival in ductal breast cancer
29Tyrosine PhosphorylationThyroid cancer/carcinomaUY18717209045
[Reference]: Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.

※ Disease Cross-ref Annotation

DatabaseAnnotation
Cancer Gene Census
CLL, ovarian mixed germ cell tumour, cervical carcinoma
CTD (Curated)
(count: 27)
(view all)
MESH:D001171 ; Arthritis, Juvenile
MESH:D002545 ; Brain Ischemia
MESH:D002294 ; Carcinoma, Squamous Cell
MESH:D009202 ; Cardiomyopathies
MESH:C566627 ; Ceroid Lipofuscinosis, Neuronal, 6
MESH:D001651 ; Cholestasis, Extrahepatic
GWASdb
(count: 6)
rs13515; Heart rate; heart conduction disease
rs2283792; Multiple sclerosis; multiple sclerosis
rs17759796; Atrial fibrillation; familial atrial fibrillation
rs8141815; Alcohol consumption (maxi-drinks); alcohol abuse|alcohol dependence
rs8141815; Heart Rate; heart conduction disease
rs9610417; Amyotrophic Lateral Sclerosis; amyotrophic lateral sclerosis

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 20)
(view all)
113       DLMETDLYKLLKTQH     dbPAF
181       ADPDHDHTGFLTEYV     dbPAF
185       HDHTGFLTEYVATRW     dbPAF
187       HTGFLTEYVATRWYR     dbPAF
190       FLTEYVATRWYRAPE     dbPAF
193       EYVATRWYRAPEIML     dbPAF
Ubiquitination
(count: 9)
(view all)
151       NVLHRDLKPSNLLLN     PLMD
164       LNTTCDLKICDFGLA     PLMD
272       LSLPHKNKVPWNRLF     PLMD
285       LFPNADSKALDLLDK     PLMD
292       KALDLLDKMLTFNPH     PLMD
330       PIAEAPFKFDMELDD     PLMD
Glycation
(count: 2)
285       LFPNADSKALDLLDK     PLMD
99        APTIEQMKDVYIVQD     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
A8MUN0P28482BioGRID
B4E335P28482BioGRID
E2QRG5P28482HPRD
E7EWZ9P28482HPRD
F5GXF0P28482HPRD
F5H146P28482BioGRID
F5H687P28482BioGRID
F8VXB4P28482HPRD
G5E9E4P28482BioGRID
H0Y465P28482BioGRID
H0YGP4P28482BioGRID
H0YHL4P28482BioGRID
H3BQN4P28482BioGRID
O14788P28482HPRD
O14901P28482HPRD
O43252P28482BioGRID
O43559P28482HPRD
O60504P28482HPRD
O75030P28482HPRD
O75676P28482HPRD
O76070P28482HPRD
O95071P28482HPRD
O95644P28482BioGRID
P00533P28482HPRD
P00750P28482HPRD
P01100P28482HPRD
P01266P28482BioGRID
P01275P28482BioGRID
P01771P28482BioGRID
P02008P28482BioGRID
P02100P28482BioGRID
P02686P28482HPRD; MINT;MINT
P02741P28482IntAct
P03372P28482HPRD
P03979P28482BioGRID
P04049P28482HPRD
P04150P28482HPRD
P04406P28482BioGRID; IntAct
P04637P28482HPRD
P05093P28482BioGRID
P05387P28482BioGRID
P05412P28482DIP
P06239P28482HPRD; MINT
P06400P28482HPRD
P07101P28482HPRD
P07339P28482IntAct
P07900P28482HPRD
P07947P28482BioGRID
P07949P28482HPRD
P08047P28482HPRD
P08138P28482HPRD
P08621P28482BioGRID
P10242P28482HPRD
P10275P28482HPRD
P10415P28482HPRD; MINT
P12036P28482HPRD
P12270P28482HPRD
P14921P28482HPRD
P15056P28482HPRD
P15309P28482MINT
P15391P28482HPRD
P15428P28482BioGRID
P15498P28482HPRD
P15923P28482HPRD
P15976P28482HPRD
P16144P28482BioGRID
P16989P28482HPRD; MINT
P17181P28482HPRD
P17302P28482HPRD
P17480P28482HPRD
P17535P28482HPRD
P17676P28482HPRD
P18031P28482HPRD
P19235P28482HPRD
P19419P28482HPRD; IntAct
P19438P28482HPRD
P19634P28482HPRD
P19793P28482HPRD
P22105P28482BioGRID
P23443P28482HPRD
P23467P28482MINT
P23469P28482HPRD; MINT
P23769P28482HPRD
P24046P28482HPRD
P26651P28482HPRD
P27708P28482HPRD
P28069P28482BioGRID
P28340P28482BioGRID
P28472P28482BioGRID
P28482P28482HPRD; BioGRID; MINT
P28482P28562HPRD; IntAct; MINT
P28482P29033BioGRID
P28482P29353HPRD
P28482P29973BioGRID
P28482P30086HPRD
P28482P30480IntAct
P28482P30533HPRD
P28482P31268BioGRID
P28482P31994HPRD
P28482P32121HPRD; IntAct; MINT
P28482P35236HPRD; MINT
P28482P35568HPRD
P28482P36507HPRD
P28482P36956HPRD
P28482P37231HPRD
P28482P37840HPRD
P28482P40763HPRD
P28482P41182HPRD
P28482P42229HPRD
P28482P42702HPRD
P28482P43146IntAct
P28482P43699HPRD
P28482P45983HPRD
P28482P46695MINT
P28482P46940HPRD
P28482P49023HPRD
P28482P49407HPRD
P28482P49588BioGRID
P28482P49795HPRD
P28482P49815HPRD
P28482P50548HPRD
P28482P50579HPRD
P28482P50616HPRD
P28482P50748BioGRID
P28482P51170HPRD
P28482P51452HPRD; MINT
P28482P51692HPRD
P28482P51812HPRD; IntAct
P28482P51955HPRD
P28482P53004DIP
P28482P53355HPRD
P28482P54829HPRD
P28482P55211HPRD
P28482P56524HPRD
P28482P58546IntAct
P28482P60201BioGRID
P28482P62136MINT;HPRD
P28482P62993HPRD
P28482P63000BioGRID
P28482P67775HPRD; MINT
P28482P67809HPRD; MINT
P28482P68133BioGRID
P28482P78352MINT
P28482P80217IntAct
P28482P84022HPRD; IntAct
P28482P98160BioGRID
P28482Q02156HPRD
P28482Q02363IntAct
P28482Q02750HPRD; MINT
P28482Q03135HPRD
P28482Q04743BioGRID
P28482Q05469HPRD
P28482Q05513HPRD
P28482Q05655HPRD
P28482Q05923HPRD; MINT
P28482Q07021HPRD
P28482Q07666HPRD
P28482Q07820HPRD
P28482Q07869HPRD
P28482Q07889HPRD
P28482Q08752DIP
P28482Q12772HPRD
P28482Q12913MINT
P28482Q13115HPRD; MINT
P28482Q13153HPRD
P28482Q13177HPRD
P28482Q13233HPRD
P28482Q13285HPRD
P28482Q13322HPRD
P28482Q13362MINT
P28482Q13480HPRD
P28482Q13485HPRD
P28482Q13501MINT
P28482Q13541HPRD
P28482Q13643HPRD
P28482Q14160IntAct
P28482Q14558IntAct
P28482Q14790HPRD; MINT
P28482Q15025HPRD; IntAct
P28482Q15121HPRD; MINT
P28482Q15256HPRD; MINT
P28482Q15349HPRD
P28482Q15418HPRD
P28482Q15583HPRD
P28482Q15788HPRD
P28482Q15796HPRD
P28482Q15797HPRD
P28482Q16288HPRD
P28482Q16539HPRD;MINT
P28482Q16595BioGRID
P28482Q16690HPRD; MINT
P28482Q16828HPRD; MINT
P28482Q16829HPRD; MINT
P28482Q3T906IntAct
P28482Q53EZ4HPRD
P28482Q53GL0MINT
P28482Q6UB98BioGRID
P28482Q6VAB6HPRD
P28482Q86UQ4BioGRID
P28482Q8IVT5HPRD
P28482Q8IW41HPRD
P28482Q8IYB3BioGRID
P28482Q8N5H7HPRD
P28482Q8N7G0BioGRID
P28482Q8N8S7IntAct
P28482Q8NEM7IntAct
P28482Q8NFZ5IntAct
P28482Q8NHW3HPRD
P28482Q8WU20HPRD
P28482Q93038HPRD
P28482Q96MX0HPRD
P28482Q96QC0BioGRID
P28482Q96RK0MINT
P28482Q96SB3HPRD
P28482Q99626HPRD
P28482Q99956HPRD; MINT
P28482Q9BRR9IntAct
P28482Q9BUB5HPRD
P28482Q9BY84HPRD
P28482Q9BYB0IntAct
P28482Q9H2C1BioGRID
P28482Q9H2K0IntAct
P28482Q9H4B4HPRD
P28482Q9H6Z9IntAct
P28482Q9H8Y8HPRD
P28482Q9HBH9HPRD
P28482Q9HCL0BioGRID
P28482Q9HD43HPRD
P28482Q9NQ66HPRD
P28482Q9NWL6BioGRID
P28482Q9NXC2BioGRID
P28482Q9NXR1HPRD
P28482Q9P1Z2HPRD
P28482Q9UHA4HPRD
P28482Q9UHM6BioGRID
P28482Q9UKE5IntAct
P28482Q9UKS6IntAct
P28482Q9ULV5HPRD
P28482Q9UMS0BioGRID
P28482Q9UQ39BioGRID
P28482Q9UQC2HPRD
P28482Q9Y463HPRD
P28482Q9Y6Q9HPRD